Targeting a Novel Target on Tumor Associated Macrophages In Triple Negative Breast Cancer – Opportunity For A First-In-Class Therapeutic

Time: 2:30 pm
day: Discovery & Pre-Clinical Development - Day 1 pm


  • Genagon has characterized a novel target within immuno-oncology specialized for cancers with a high infiltration of macrophages.
  • The target accumulates on the surface of cells within the tumor, enabling treatment with low risk of side-effects
  • Genagon is targeting novel biology with an opportunity for a first- in-class therapeutic in the $500 million market triple negative breast cancer.